31 results about "EYE INFESTATION" patented technology

The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-Vascular Endothelial Growth Factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal. In particular, the invention provides a method for delivering the aptamer to an eye for the treatment of an ocular disorder, for example, age-related macular degeneration.

There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin, deoxypicropodophyllin and anhydropicropodophyllol. There is also described a method of treatment of an eye disease.

The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.

The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.

The present invention comprises a composition and methods for treating eye conditions using a composition having a therapeutically effective amount of a progestagen, or a therapeutically effective amount of a progestagen with a testosterone; and pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and / or ocular surface.

The present invention provides a method for treating and / or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and / or inosine.

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.

The present invention is one group of carotenoid antioxidant recipe comprising lutin and / or rutin ester, zeaxanthin and / or zeaxanthin ester and other antioxidant. Several medicinal and health care antioxidant products may be produced to avoid, delay or treat the harmful effect of the free radical caused by light, cigarette and hormone to eye, especially its crystalline lens and retina. The present invention is used mainly for the prevention and treatment of age relevant eye diseases, cataract, macular degeneration, etc. Dihydroxy carotenoid and other antioxidant are used to nourish crystalline lens and retina so as to enhance the capacity of eye, especially its crystalline lens and retina, in resisting the effect of outer negative factors.

The present invention comprises a composition and method treating eye diseases using a composition having a therapeutically effective amount of a progestagen and a pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye and / or ocular surface.

A method of treating ocular disorders (such as, for example, proliferative vitreoretinopathy or PVR) associated with replicating ocular cells by transfecting replicating ocular cells in vivo with a polynucleotide encoding an agent which is capable of providing for the inhibition, prevention, or destruction of the growth of the replicating ocular cells upon expression of the agent. The agent may be a viral thymidine kinase, and the polynucleotide encoding the agent may be contained in a retroviral vector. Once the replicating ocular cells are transduced with the retroviral vector, the patient is given a chemotherapeutic or interaction agent, such as ganciclovir, which kills the transfected replicating ocular cells.

The invention relates to composition instant granules for providing nutrients for the macular area of the retina, improving vision and preventing eye diseases and a preparation method thereof, and belongs to the field of functional nutritious food. The composition instant granules are prepared from, by weight, 1.5 parts of a blueberry extract, 5 parts of a bilberry extract, 2.5 parts of a dunaliella salina extract, 0.5 part of zeaxanthin, 0.2 part of lutein ester, 6.5 parts of tea theanine, 10 parts of a fructus lycii extract, 5 parts of a haematococcus pluvialis extract, 5 parts of DHA algaeoil microcapsule powder, 10 parts of acerola cherry fruit powder, 0.15 part of taurine, 0.15 part of zinc gluconate, 0.15 part of calcium, 0.15 part of organic selenium, 0.15 part of vitamin B2, 0.15part of vitamin E, 0.15 part of casein phosphopeptide and 50 parts of xylitol. The composition instant granules can provide the nutrients for the macular area of the retina, delay the increase of thedegree of myopia of adolescents, assist in treating amblyopia of infants, delay the occurrence of presbyopia of middle-aged and elderly people, prevent the eye diseases of middle-aged and elderly people, and assist in treating the eye diseases of middle-aged and elderly people.

The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.

The invention relates to an eye drop, in particular to a penetration promoting and eyesight improving eye drop. The invention aims to solve the problem of treatment period prolongation of an eye disease due to less effective components of the traditional eye drop, which really enter the inner side of an eyeball, by the isolation of a blood-eye barrier, a cornea barrier and an eye surface barrier. A penetration promoting and eyesight improving medicament in the first scheme is any combination of one or more of borneol, menthol, taurochenodeoxycholic acid or tauroursodeoxycholic acid; and a penetration promoting and eyesight improving medicament in the second technical scheme is any combination of one or more of borneol, menthol, chenodeoxycholic acid or ursodesoxycholic acid. The eye drop is used for a patient with conjunctivitis, keratitis and uveitis and used as a penetration promoting agent of other eye drops or an ophthalmic pharmaceutical partner for increasing the amount of the eye drops dropping in eyes. The eye drop can penetrate through the blood-eye barrier, the cornea barrier and the eye surface barrier; and compared with the prior art, the invention can improve the effective component entering the inner side of the eyeballs by 10-200 percent.

The present invention provides a combination of rebamipide and a tear-retaining agent as a medicament for the treatment of anterior eye diseases.

The present invention provides a safer and more effective way to treat ophthalmic disease and to perform ophthalmic surgeries while reducing the risk of vision loss due to the inflammatory response in the eye. The invention generally relates to the use of fluoroquinolones to reduce inflammation due to ophthalmic disease or ophthalmic surgery, including treatments for macular degeneration, diabetes, and vascular ischemic diseases, and other ophthalmic diseases. One aspect of the present invention involves using an anti-VEGF medication along with moxifloxacin in treating ophthalmic disease and in reducing inflammatory response in the eye following surgery for treating diseases like wet macular degeneration. Another aspect of the present invention involves delivering a fluoroquinolone combination to the eye in a sustained delivery application or device.

Several embodiments disclosed herein relate to the delivery of therapeutic nucleic acids to an ocular tissue in order to provide a therapeutic effect to reduce symptoms of or otherwise alleviate an ocular disorder. In particular embodiments, plasmid DNA is delivered to the cells of the trabecular meshwork in order to ameliorate increasing intraocular pressure. Devices and systems to accomplish this delivery are also disclosed.

The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.

The present invention belongs to the biological field and the medical field, which relates to an adenovirus composite preparation for a new genetic therapy as well as the application and the application method. The present invention demonstrates that when the adenovirus is taken as a gene delivery vector, the combined use of adenovirus with a certain dose of antitumor drug can dramatically enhance the foreign gene expression of the adenovirus and significantly prolong the period of the foreign gene expression, and the therapy effect of the gene is improved. The composite preparation and the application method of the present invention can be applied as a guide of the genetic therapy of the malignant tumor, the eye disease, the genetic disease, the cardiovascular disease and the neuromuscular disorder, etc.

Described herein are pharmaceutical compositions containing Adelmidrol. In particular, the Adelmidrol is used in the treatment of diseases characterized by insufficient specific agonism of the PPAR-gamma receptor in humans or animals, more particularly in the treatment of articular chondropathies of mechanical, toxic, iatrogenic, degenerative origin, or associated with inflammatory phenomena mainly related to organs and tissues not belonging to the osteoarticular system; fibrogenesis of the articular cartilages; chronic inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis; Irritable Bowel Syndrome (IBS); diseases characterized by an abnormal fibrosis of the connective tissue, such as systemic sclerosis, particularly of the skin and lung; eye disorders characterized by angiogenesis, fibrosis, inflammation and oxidative stress.

The eye drop of deep sea water features that it contains deep sea water to replace antibiotic and preservative. It has antiseptic and antiphlogistic effect, and functions of providing eye tissue with rich trace elements and nutritious components, remitting eye's fatigue and repairing eye's damage. It has no hidden hazard caused by antibiotic and preservative, no dependence and no toxic side effect.

The invention provides methods for treating and / or preventing ocular disorders associated with increased intraocular pressure comprising administering a non-peptide bradykinin agonist to a patient in need thereof.

A method comprising the step of: administering an effective amount of a topical dipyridamole to a subject in need thereof due to an eye disorder selected from the group consisting of pterygium and pinguecula.

Provided is a composition for prophylaxis or treatment of an eye disease comprising a compound represented by General Formula I:S-(MS)p-(MS)q  General Formula Iwherein S represents sialic acid, and (MS)p and (MS)q independently represent a monosaccharide residue.The compound used as the active ingredient inhibits expression of MMP-9 and inflammation-mediated cytokines (IL-1β, TNF-α, etc.) in corneal epithelial cells and inhibits VEGF-mediated VEGFR-2 activation in human retinal endothelial cells (HREC), thereby exhibiting prophylactic or therapeutic activity for eye diseases such as dry eye syndrome, inflammatory eye disease, neovascularization-associated eye disease and side effects of wearing of contact lenses. Also, because it has no cytotoxicity or skin side effect, the provided composition may be safely used as a pharmaceutical composition, a neutraceutical composition or a food composition. In addition, the composition may be used as a cleaner or a lubricant for contact lenses since it has nonbacterial antiinflammatory activity and ocular contact lubricating activity.

The present invention relates to a composition for preventing or treating dry eye syndrome or eye diseases caused by dry dyes, containing imatinib as an active ingredient and, more specifically, to an eye bath lotion for preventing or treating dry eye syndrome or eye diseases associated with dry eye syndrome, containing imatinib an active ingredient. Imatinib of the present invention effectively protects the corneal epithelia and inhibits the degeneration thereof, thereby being usable for a use of alleviating or treating dry eye syndrome or eye diseases associated with dry eye syndrome.